Treatments for platinum-resistant ovarian cancer are expanding with new FDA-approved immunotherapy combinations and targeted ...

On Monday, Merck & Co Inc (NYSE:MRK) announced topline data from the Phase 3 KEYLYNK-001 trial. The trial evaluating Keytruda (pembrolizumab) plus chemotherapy followed by maintenance with Lynparza ...

NICE has recommended mirvetuximab soravtansine for resistant ovarian cancer, citing better survival and a less burdensome treatment experience.

Adding bevacizumab to the combination therapy of carboplatin and paclitaxel significantly improved progression-free survival (PFS) in patients with epithelial ovarian cancer (EOC) but not overall ...

Updated findings from the phase 3 ROSELLA trial showed that patients with platinum-resistant ovarian cancer continued to experience an overall survival benefit with Lifyorli (relacorilant) plus ...

ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO ...

Merck's KEYLYNK-001 trial showed Keytruda and Lynparza improved progression-free survival in BRCA non-mutated ovarian cancer patients. In the waveLINE-007 trial, zilovertamab vedotin with R-CHP ...